About this trial
Last updated a year ago
Study ID
P10-023
Status
Completed
Type
Observational
Placebo
No
Accepting
18 to 99 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 2 years ago
What is this trial about?
The purpose of this study is to evaluate the long-term safety of Humira® in Adult
Patients with Chronic Plaque Psoriasis (Ps).
What are the participation requirements?
Inclusion Criteria
1. An adult patient (18 years of age or older) with chronic plaque psoriasis who has been prescribed HUMIRA® therapy according to the local product labeling and meets one of the following criteria:
- New initiated (within 4 weeks of registry entry) on HUMIRA® therapy;
- Initiated HUMIRA® therapy in the past and:
- Has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy and the physician can provide source documentation of SAEs, AEs, of Special Interest, and dosing information since initiation of therapy. OR
- Is entering after participation in an AbbVie HUMIRA (adalimumab) sponsored study and has received continuous (no more than 70 consecutive days off drug) HUMIRA® therapy after the completion of AbbVie sponsored study and physician can provide source documentation of SAEs, AEs of Special Interest, and dosing information since initiation of commercial HUMIRA® (defined as a prescribed/non study drug).
2. Patient is willing to consent to data being collected and provided to AbbVie;
3. Patient is capable of and willing to give written informed consent and to comply with the requirements of the registry.
Exclusion Criteria
- Patient should not be enrolled if he/she cannot be treated in accordance with the local product label.
For more information, view the full study details:
NCT00799877